AG真人官方

Air Industries Group (AIRI) filed a Form S-8 on 31 Jul 2025 to register 300,000 additional shares of common stock for issuance under its 2022 Equity Incentive Plan. The amendment, approved at the 2024 annual meeting, raises the plan鈥檚 share reserve from 350,000 to 650,000.

The company is classified as a non-accelerated filer and smaller reporting company. The filing automatically incorporates by reference AIRI鈥檚 2024 Form 10-K, Q1-25 Form 10-Q, numerous 2025 Form 8-Ks, and its 2025 definitive proxy, ensuring that all subsequent Exchange Act filings will also be deemed incorporated until the offering is completed or withdrawn.

Key exhibits include: (1) legal opinion from Ellenoff Grossman & Schole LLP, (2) the amended 2022 Equity Incentive Plan, (3) auditor consent from Marcum LLP, and (4) the Rule 457 filing-fee table. Part II outlines Nevada law鈥揵ased indemnification provisions for directors and officers and confirms the company carries D&O insurance. Standard undertakings commit AIRI to file post-effective amendments if material changes arise.

Form 144 filing for MongoDB, Inc. (MDB) reports a planned sale of 2,000 common shares via Morgan Stanley Smith Barney. The transaction, valued at $500,000 (鈮� $250 per share), is expected to occur on 31 Jul 2025 on the NASDAQ.

The company lists 81,714,313 shares outstanding, so the proposed sale represents only ~0.003 % of shares outstanding. All shares were obtained as restricted-stock grants between 2019-2021.

The filer鈥攚hose recent activity shows a 265-share sale for $54,603.25 on 2 Jul 2025鈥攃ertifies that no undisclosed adverse information about MongoDB exists. No operational or earnings data accompany this notice; it solely concerns this secondary sale.

Form 144 filing for MongoDB, Inc. (MDB) reports a planned sale of 2,000 common shares via Morgan Stanley Smith Barney. The transaction, valued at $500,000 (鈮� $250 per share), is expected to occur on 31 Jul 2025 on the NASDAQ.

The company lists 81,714,313 shares outstanding, so the proposed sale represents only ~0.003 % of shares outstanding. All shares were obtained as restricted-stock grants between 2019-2021.

The filer鈥攚hose recent activity shows a 265-share sale for $54,603.25 on 2 Jul 2025鈥攃ertifies that no undisclosed adverse information about MongoDB exists. No operational or earnings data accompany this notice; it solely concerns this secondary sale.

Arteris, Inc. (AIP) Form 144 discloses a planned secondary sale of the company鈥檚 common stock.

The Saiyed Atiq Raza & Nandini Saraiya 2012 Revocable Trust intends to sell 82,405 shares through Morgan Stanley on or about 29 Jul 2025. At the filing鈥檚 reference value (~$9.45 per share), the block equals $778,727 and represents roughly 0.20 % of the 41.98 million shares outstanding.

The shares were acquired as restricted stock units on 15 Dec 2022. Rule 144 requires the filer to affirm it possesses no undisclosed material adverse information.

Within the last three months the same trust already sold 20,945 shares (6/27 & 7/18/25) for $209,852. Combining those sales with the new notice raises potential disposals to ~0.25 % of the share base.

This filing does not alter Arteris鈥檚 operations or outlook but alerts investors to modest upcoming insider-related liquidity that could create limited near-term supply pressure.

Arteris, Inc. (AIP) Form 144 discloses a planned secondary sale of the company鈥檚 common stock.

The Saiyed Atiq Raza & Nandini Saraiya 2012 Revocable Trust intends to sell 82,405 shares through Morgan Stanley on or about 29 Jul 2025. At the filing鈥檚 reference value (~$9.45 per share), the block equals $778,727 and represents roughly 0.20 % of the 41.98 million shares outstanding.

The shares were acquired as restricted stock units on 15 Dec 2022. Rule 144 requires the filer to affirm it possesses no undisclosed material adverse information.

Within the last three months the same trust already sold 20,945 shares (6/27 & 7/18/25) for $209,852. Combining those sales with the new notice raises potential disposals to ~0.25 % of the share base.

This filing does not alter Arteris鈥檚 operations or outlook but alerts investors to modest upcoming insider-related liquidity that could create limited near-term supply pressure.

Arteris, Inc. (AIP) 鈥� Form 4 insider transaction

Director S. Atiq Raza reported a sale of 1,136 common shares on 18-Jul-2025 at a reported price of $10.00 per share. The disposition was executed under a previously adopted Rule 10b5-1 trading plan dated 6-Jun-2024.

Following the sale, Raza continues to hold a large position: 682,662 shares held indirectly through the Saiyed Atiq Raza & Nandini Saraiya 2012 Revocable Trust and 20,839 shares held directly. The transaction reduced his total ownership by roughly 0.16%, indicating only a marginal change in economic exposure while maintaining significant alignment with shareholders.

Arteris, Inc. (AIP) 鈥� Form 4 insider filing

Director Joachim Kunkel reported the acquisition of 1,727 fully-vested restricted shares of Arteris common stock on 07/05/2025. The shares represent board retainer fees that Mr. Kunkel chose to receive in stock rather than cash; the filing states the director also elected to defer receipt of these shares. The transaction was recorded at a price of $0.00 because it is compensation-related, not an open-market purchase. Following the award, Mr. Kunkel鈥檚 direct ownership increases to 66,322 shares. No derivative security activity was reported.

The filing indicates Mr. Kunkel remains classified as a Director and files individually. No amendments or additional reporting persons are noted.

While the award is modest in size, insider share accumulation鈥攅specially when taken in lieu of cash鈥攎ay signal greater alignment with shareholder interests. However, because it is routine compensation rather than a discretionary market purchase, the market impact is likely limited.

Arteris, Inc. (AIP) 鈥� Form 4 insider transaction filing

Vice President & Chief Financial Officer Nicholas B. Hawkins reported four open-market sales totalling 8,837 common shares during July 2025 at a weighted-average price of approximately $9.09 per share.

• 07/02/2025: Three sales (1,489 sh, 891 sh, 1,509 sh) at $8.9924 each, executed solely to satisfy tax-withholding obligations stemming from the release of restricted stock units (RSUs).
• 07/07/2025: Sale of 4,948 sh at a weighted average price of $9.2207; transaction executed under a pre-arranged Rule 10b5-1 trading plan adopted on 20-May-2024.

After these transactions, Hawkins鈥� direct beneficial ownership stands at 130,548 shares, down from roughly 139,385 shares, a reduction of about 6.3 % of his prior holdings. No derivative security activity was reported.

The filing does not disclose any option exercises, purchases, or new awards. All sales were made on the open market; the price range for the 07/07 trades was $9.00鈥�$9.35.

Because a portion of the shares sold covered RSU-related tax liabilities and the remainder was executed under a previously established 10b5-1 plan, the transactions appear routine rather than opportunistic. Nevertheless, investors may note the modest decrease in insider ownership by a key executive.

Arteris, Inc. (AIP) 鈥� Form 4 insider transaction filing

Vice President & Chief Financial Officer Nicholas B. Hawkins reported four open-market sales totalling 8,837 common shares during July 2025 at a weighted-average price of approximately $9.09 per share.

• 07/02/2025: Three sales (1,489 sh, 891 sh, 1,509 sh) at $8.9924 each, executed solely to satisfy tax-withholding obligations stemming from the release of restricted stock units (RSUs).
• 07/07/2025: Sale of 4,948 sh at a weighted average price of $9.2207; transaction executed under a pre-arranged Rule 10b5-1 trading plan adopted on 20-May-2024.

After these transactions, Hawkins鈥� direct beneficial ownership stands at 130,548 shares, down from roughly 139,385 shares, a reduction of about 6.3 % of his prior holdings. No derivative security activity was reported.

The filing does not disclose any option exercises, purchases, or new awards. All sales were made on the open market; the price range for the 07/07 trades was $9.00鈥�$9.35.

Because a portion of the shares sold covered RSU-related tax liabilities and the remainder was executed under a previously established 10b5-1 plan, the transactions appear routine rather than opportunistic. Nevertheless, investors may note the modest decrease in insider ownership by a key executive.